Echinocandin-Induced Microevolution of Candida parapsilosis Influences Virulence and Abiotic Stress Tolerance
Open Access
- 26 December 2018
- journal article
- research article
- Published by American Society for Microbiology in mSphere
- Vol. 3 (6) , e00547-18
Abstract
Candida parapsilosis is an opportunistic fungal pathogen with the ability to cause infections in immunocompromised patients. Echinocandins are the currently recommended first line of treatment for all Candida species. Resistance of Candida albicans to this drug type is well characterized. C. parapsilosis strains have the lowest in vitro susceptibility to echinocandins; however, patients with such infections typically respond well to echinocandin therapy. There is little knowledge of acquired resistance in C. parapsilosis and its consequences on other characteristics such as virulence properties. In this study, we aimed to dissect how acquired echinocandin resistance influences the pathogenicity of C. parapsilosis and to develop explanations for why echinocandins are clinically effective in the setting of acquired resistance.Keywords
Funding Information
- GINOP (GINOP-2.3.2-15-2016-00035)
- NKFIH (K123952)
- Hungarian Academy of Sciences (LP2018-15/2018)
- Spanish Ministry of Economy (BFU2015-67107)
- Catalan Research Agency (SGR857)
- EC | Horizon 2020 Framework Programme (ERC-2016-724173)
- EC | Horizon 2020 Framework Programme (H2020-MSCA-ITN-2014-642095)
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (PDCPN2014-247109, FC 2015-02-834)
- Universidad de Guanajuato (1025/2016, CIIC 95/2018)
This publication has 51 references indexed in Scilit:
- Emergence of non-Candida albicans species: Epidemiology, phylogeny and fluconazole susceptibility profileJournal of Medical Mycology, 2018
- Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungalsMycoses, 2017
- Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: A 10‐year studyMycoses, 2017
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2015
- Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines.2014
- Antifungal Susceptibility Testing of Candida Isolates from the Candida Surveillance StudyJournal of Clinical Microbiology, 2010
- Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006)Critical Care Medicine, 2009
- Candida parapsilosis, an Emerging Fungal PathogenClinical Microbiology Reviews, 2008
- Epidemiology, Risk Factors, and Prognosis of Candida parapsilosis Bloodstream Infections: Case-Control Population-Based Surveillance Study of Patients in Barcelona, Spain, from 2002 to 2003Journal of Clinical Microbiology, 2006
- Candida glabrata Fungemia: Experience in a Tertiary Care CenterClinical Infectious Diseases, 2005